图文详情
CP-547632 TFA is an orally active, ATP-competitive inhibitor that potently targets VEGFR-2 and FGF kinases with IC50 values of 11 nM and 9 nM, respectively. It demonstrates selectivity for VEGFR-2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs), exhibiting antitumor efficacy [1].